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Abstract: The pharmacovigilance databases consist of several case reports 
involving drugs and adverse events (AEs). Some methods are applied consistently 
to highlight all signals, i.e. all statistically significant associations between a drug 
and an AE. These methods are appropriate for verification of more complex 
relationships involving one or several drug(s) and AE(s) (e.g; syndromes or 
interactions) but do not address the identification of them. We propose a method 
for the extraction of these relationships based on Formal Concept Analysis (FCA) 
associated with disproportionality measures. This method identifies all sets of 
drugs and AEs which are potential signals, syndromes or interactions. Compared 
to a previous experience of disproportionality analysis without FCA, the addition 
of FCA was more efficient for identifying false positives related to concomitant 
drugs. 
Keywords: Adverse Effects, Formal Concept Analysis, Data analysis-extraction 
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1. Introduction 
Detecting unexpected relationships between drugs and adverse events (AEs) from a 
pharmacovigilance database is a real challenge. Automated signal detection consists in 
application of data mining algorithms to help identification of signals, i.e. all 
statistically significant {drug, AE} couples, which are numerous and should be reduced 
to the most plausible [1]. Indeed, these potential signals extracted from a database are 
only assumptions; they should lead to more complex and expensive pharmacological 
studies. Therefore, it’s important not to ignore any relationships but avoid an excess of 
studying situations. 
Several types of relationships can be identified from the database: (i) {drug, AE} 
couples that data mining algorithms have mainly focused on; (ii) Relationships between, 
two drugs and an AE which are potential drug interactions, (iii) Relationships between 
several AEs and a drug which are potential syndromes, (iv) Relationships involving 
several drug(s) and AE(s) which are frequently observed in protocols. Among 
relationships between several drugs, cases where the drug association strengthens a 
signal compared to both single drugs may be classified as a potential interaction. Cases 
where there is no signal between one of the drugs and the AE are more difficult to 
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interpret and may be related to concomitant drugs: the first drug is responsible for the 
AE but the second drug is only an innocent bystander which was associated to the first 
drug by chance or due to a frequent therapeutic association. 
Automated methods for detecting drugs-AEs relationships are based on calculation 
of disproportionality measures. The statistical approach includes the Proportional 
Reporting Ratio (PRR) [2], χ² often coupled with the PRR, and the Reporting Odds 
Ratio [1]. The Bayesian approach consists of the Multi-item Gamma Poisson Shrinker 
algorithm [3] and the Bayesian Confidence Propagation Neural Network [4]2. Recently, 
van Puijenbroek et al have used these methods in the detection of drug interactions [5] 
using a model based on logistic regression. These methods are appropriate for 
verification of more complex relationships involving several drugs and/or AEs (e.g; 
syndromes or interactions) but do not address the identification of them. A syndrome 
detected by case review involving Terbinafine and three AEs (arthralgia, urticaria and 
fever) was verified using this model [6]. A couple of articles addressed verification of 
already known drug interactions based on pharmacological knowledge. No systematic 
research and verification of relationships involving several drugs and/or syndromes 
was described in the literature with data mining algorithms. 
Our new approach detects all kinds of drugs-AEs relationships thanks to an 
exhaustive exploration of a pharmacovigilance database. It helps identifying situations 
where drugs are prescribed together whereas a previous method [7] generated several 
false positives due to the innocent bystanders. It is based on Formal Concept Analysis 
(FCA) [8] combined with disproportionality measures. This article introduces briefly 
FCA and its use in pharmacovigilance, and then presents the results of an application of 
this method to an extract of the French pharmacovigilance database. We finally 
conclude with a discussion of the results. 
2. Materials and Methods 
2.1. Fundamentals of Formal Concept Analysis (FCA) 
The central notion in Formal Concept Analysis [8] is a hierarchical structure called 
Concept Lattice where objects are classified following the attributes they own. The set 
of objects ( ) and attributes ( ) together with their relation to each other ( ) 
is called a formal context . Table in figure 1(a) defines a formal context for 
adverse drug event exploration, where  is a set of patients and is the set of 
attributes: sex (male and female), drugs that patients took (D1, D2, D3, D4, D5) and 
adverse events (AE1, AE2). Two derivation operators, both denoted by ' link objects 
and attributes. Let  and  then and 
. Two compound operators both noted " are defined by the 
composition of the two ' operators (i.e. " = ' o '). They are closure operators over  (": 
O→O) and  (": A→A). A pair of '-connected sets is called formal concept: 
 is a formal concept iff  and .  and  are respectively the 
extent and the intent of the concept. The set  of all concepts of the context is 
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partially ordered by inclusion  on : .  is a 
concept lattice. 
In the context given figure 1(a),  but, following the previous 
definition, the formal concept built by closure is . The lattice 
 has one top concept which extent groups all the objects of the context and, 
by duality, one bottom concept which intent groups all the attributes of the context. 
Objects in the extension of a concept are inherited from the bottom to the top of the 
lattice. In a dual way, attributes are inherited from top to bottom. Figure 1(b) is the 
concept lattice of the context (a). The concept  is named in 
the lattice. 
 
 
 M F D1 D2 D3 D4 D5 AE1 AE2 
P1 X  X  X   X  
P2 X  X  X   X  
P3 X  X  X   X  
P4  X X     X  
P5  X  X  X   X 
P6  X  X  X   X 
P7  X  X  X   X 
P8  X     X X X 
  
Figure 1: (a) Context describing patients. (b) The corresponding concept lattice 
2.2. FCA and Adverse Drug Event Exploration 
The intent of some formal concepts shows that some patients took a same set of drugs 
and had the same set of AEs. In , four patients  took the drug and 
have the adverse event . We also observe in the context that , among others, 
also took  but is the only drug that the four patient  took. Thanks 
to the closure operators used to build the concepts, the lattice gives all the drugs-AEs 
relationships that exist in the data and no more. Among all the concepts, we distinguish 
potential signals, when the intent includes only one drug and one AE (see  and ); 
potential drug interactions, when the intent includes two drugs and one AE (see  
and ); and potential syndrome, when the intent includes one drug and several AEs 
(see ). 
Compared to extraction of {drug, AE } couples without FCA, the lattice – with its 
formal concepts built using the closure operators – reduces the number of situations 
drugs-AEs to study. In figure 1(b), patients share the attributes . 
While disproportionality measures would propose two potential signals to study 
(  and ), the lattice keeps only one ( ) as  is not 
shared by any group of patients. Of course, thresholds used in disproportionality 
measures are not meaningful on such a small example. 
All formal concepts are not relevant for adverse drug event exploration. Either they 
do not describe a drug-AEs relationship or the described relationship is not statistically 
significant. To keep statistically significant concepts when the intent includes drugs 
and AEs, we combine the lattice with criteria used by the British Medicines and 
Healthcare products Regulatory Agency (MHRA): χ² > 4, PRR > 2 and the number of 
patients (the support) is greater or equal to 3 (see [2] for χ² and PRR calculation). The 
a,b,c and d parameters for χ² and PRR calculation are calculated from the extent of 
concepts in the lattice. We tested this method to a subset of 3249 cases from the French 
database on AEs. Drugs where encoded as active ingredients and AEs where encoded 
following the WHO-ART terminology. In that way, our database contains 527 drugs 
and 639 AEs. First, the lattice has been built using the Galicia software and then, for 
any concept whose support is higher than 3, we calculated both PRR and χ² values. 
3. Results 
The whole lattice has 13,178 concepts. For 842 of them, the intent includes at least one 
drug and one AE. Relationships are investigated using MHRA criteria in a horizontal 
strip of the lattice (see black circles in figure 2b). This remaining strip is delimited in 
the upper part according to the meets, which are the first concepts of the lattice starting 
from the top including both drugs and AEs in their intent. Delimitation in the lower 
part is according to the support of concepts because we keep concepts including at least 
three patients in their extent. 
 
Concepts Count 
Total 13,178 
{D1, … Dn; AE1 … AEm} 842 
{D1, … Dn; AE1 … AEm}  
with PRR>2, χ²>4, Support ≥ 3 
593 
  
Figure 2: Concepts of the lattice before and after filtering with the MHRA criteria. (a) Results of our 
application on 3249 pharmacovigilance cases. (b) A graphical representation of conserved concepts (black 
circles) in a fictitious lattice. 
 
Table 1. Drug-AEs relationships detected with FCA after filtering with the MHRA criteria 
Relationship Count Type 
{D1; AE1} 360 Potential signal 
{D1, D2; AE1} 110 Potential drug interaction 
{D1; AE1 … AEm} 56 Potential drug syndrome 
{D1, … Dn; AE1} 42 Potential complex interaction 
{D1, … Dn; AE1 … AEm} 25 Potential complex syndrome 
Total 593 PRR>2, χ²>4, support ≥ 3 
Meet 
Support ≥ 3 
Table 1 shows five different kinds of drug-AEs detected relationship. 181 among 
the 360 concepts expressing a potential signal are not restricted to a given population 
(their intent do not include any patient properties, neither age nor sex) We evaluated a 
sample of 95 of them: 61 signals where already known, for example {Abciximab, 
Thrombopenia}; 34 were not described in the literature, for example {Lidocaine, 
Tachycardia} and need further investigations. Among the 56 potential syndromes, 53 
consisted of two AEs and three consisted of three AEs. 
 
Table 2. Classification of potential drug interactions 
Drug association Count Example 
Therapeutic associations 57 Fluorouracil + oxaliplatine 
Successive prescriptions 8 Heparin + enoxaparin 
Medicinal product 22 Amoxicillin + clavulanic acid 
Concomitant drugs 23 Heparin + sucralfate 
Total 110  
 
The lattice helps to identify 110 pairs of drugs that might be classified as drug 
interactions. Among 57 pairs related to drugs commonly prescribed in therapeutic 
associations, 34 were dedicated to anti-HIV prescriptions. In 8 cases the associated 
drugs were likely to be prescribed successively rather than at the same time for 
example heparin was prescribed first then replaced by enoxaparin. 
4. Discussion and conclusion 
We evaluated in this article the properties of the concept lattice for generating 
potential relationships between one or several drugs and AEs. Sample size was 
sufficient for generating several signals. Syndromes mainly consisted of two AEs. No 
database on syndromes is available to verify their plausibility but we were able to 
detect known patterns such as hypersensitivity to abacavir. FCA also highlighted more 
complex relationships that are more difficult to interpret because they are associations 
of more than two drugs and AEs. This could help the generation of signals related to a 
whole protocol instead of single drugs. Due to sample size few drug interactions were 
detected and the interest of the lattice was more focused on the identification of false 
positives and concomitant drugs. 
In a previous experience [7], disproportinality measures extracted 523 statistically 
significant {drug, AE} couples with many false positives due to concomitant 
prescription. The new approach generates only 360 signals. Indeed many signals 
generated with the previous approach are now clustered in concept nodes of the lattice 
that present higher order relations, i.e. several drugs and/or AEs. FCA helps to reduce: 
1. The number of signals to review. For example the medicinal product 
consisting of tiemonium + colchicine + opium generated a single signal for the 
whole association whereas the previous method generated three different 
signals related to each single active ingredient. 
2. The number of false positives related to several active ingredients in the same 
medicinal products. In previous method a signal of diarrhoea was generated 
with opium whereas this active ingredient is added in small proportions to 
colchicine in order to reduce the diarrhoea episodes. Compound active 
ingredients are clustered by the current method and it is easier to interpret 
diarrhoea as related to colchicine. 
3. The number of false positives related to concomitant drugs. For example 
sucralfate was no longer associated to thrombopenia while all patients taking 
sucralfate were also prescribed heparin. 
We showed how FCA may be combined with disproportionnality measures for the 
identification of three kinds of relationships of great interest in pharmacovigilance: 
signals, drug interactions and syndromes. Building formal concepts by closure with 
FCA ensures that resulting relationships (signals, interactions and syndromes) are 
relevant relationships present in data. Thus in the case of signals, the count of 
associations the expert has to evaluate is reduced from the number of signals that 
would be generated by a classical signal detection method. 
The method we presented performs exhaustive search of the three kinds of existing 
relationships in data. This suggests new relationships for evaluation by experts, 
especially in the case of interactions and syndromes, present in data with no a priori of 
the domain. 
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